On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...
Aristotle Capital’s Global Equity Composite posted a total return of -7.72% gross of fees (-7.80% net of fees). Click here to ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback